Sigma Planning Corp acquired a new position in Actuate Therapeutics in the fourth quarter valued at approximately $128,000. Northwestern University acquired a new position in Actuate Therapeutics ...

Actuate Therapeutics (NASDAQ:ACTU – Free Report) – Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Actuate Therapeutics in a research note issued on ...

Fintel reports that on March 17, 2025, HC Wainwright & Co. initiated coverage of Actuate Therapeutics (NasdaqGM:ACTU) with a Buy recommendation. As of March 4, 2025, the average one-year price ...

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...

Actuate Therapeutics, Inc. operates under the (NASDAQ:ACTU) ticker and is classified under the pharmaceutical preparations industry, with its headquarters located in Fort Worth, Texas. Despite ...

Sigma Planning Corp bought a new position in shares of Actuate Therapeutics (NASDAQ:ACTU – Free Report) during the 4th quarter, according to the company in its most recent filing with the ...

H.C. Wainwright initiated coverage of Actuate Therapeutics (ACTU) with a Buy rating and $20 price target Actuate is a clinical-stage ...

Actuate Therapeutics’ (NASDAQ:ACTU – Get Free Report) lock-up period will end on Monday, February 10th. Actuate Therapeutics had issued 2,800,000 shares in its IPO on August 13th. The total ...

Given this risk, we thought we'd take a look at whether Actuate Therapeutics (NASDAQ:ACTU) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual ...